Soleno Therapeutics Option Alert: May 16 $50 Calls at the Ask: 999 vs 0 OI; Earnings 5/8 After Close [est] 

Soleno Therapeutics Option Alert: May 16 $50 Calls at the Ask: 999 @ $10.9 vs 0 OI; Earnings 5/8 After Close [est] Ref=$49.435

Soleno Therapeutics (NASDAQ:SLNO) Stock

SOLENO THERAPEUTICS INC

Soleno Therapeutics

Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.

Soleno Therapeutics Inc

WIIM

APLM

Apollomics shares are trading lower. The company reported FY24 financial results.

OpenAI, led by CEO Sam Altman, has spent the past two years in fierce competition with rivals Google Gemini, Anthropic, DeepSeek and Elon Musk&#8216;s xAI. Altman announced Friday that the San Francisco-based company&#8217;s <a href="https://www.benzinga.com/tech/25/03/44577187/sam-altman-led-openai-releases-open-weight-ai-model-with-reasoning-capabilities-as-deepseek-and-meta-taste-s">model release schedule</a> will undergo an important change.
What Happened: OpenAI had intended to shelve its o3 and o4 models <a href="https://www.benzinga.com/25/02/43682008/openai-phases-out-standalone-o3-gpt-5-to-offer-unified-aialtman-reveals-vague-release-timelines-after-admitting-we-hate-the-model-picker-as-much-as-you-do">earlier this year</a>, planning to integrate them into the company&#8217;s upcoming GPT-5. At the time, Altman said he wanted to simplify OpenAI&#8217;s model offerings.
On Friday, Altman announced that the company was reversing course, anticipating the release of o3 and o4 in a &#8220;couple of weeks&#8221; before rolling out the long-awaited GPT-5 in 2025.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">change of plans: we are going to release o3 and o4-mini after all, probably in a couple of weeks, and then do GPT-5 in a few months. there are a bunch of reasons for this, but the most exciting one is that we are going to be able to make GPT-5 much better than we originally…
&mdash; Sam Altman (@sama) <a href="https://twitter.com/sama/status/1908167621624856998?ref_src=twsrc%5Etfw">April 4, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
&#8220;we were able to really improve on what we previewed for o3 in many ways; i think people will be happy…,&#8221; Altman <a href="https://x.com/sama/status/1908167790336651720">said</a> in a reply. The entrepreneur believes GPT-5 will be &#8220;much better&#8221; than originally thought, but the company will need additional capacity to support user demand.
Why it Matters: OpenAI has repeatedly pushed back the <a href="https://www.benzinga.com/news/24/03/37838131/openai-is-reportedly-gearing-up-to-release-a-significantly-better-gpt-5-by-mid-year">release of GPT-5</a>.
While the company&#8217;s flagship ChatGPT is the most popular AI model in the world, competitors have rapidly improved their offerings. Anthropic, a Jeff Bezos-backed AI startup, one-upped OpenAI in some areas in its <a href="https://www.benzinga.com/25/02/43927621/anthropic-releases-most-intelligent-llm-yet-how-does-it-compare-to-openai-deepseek">update of Claude</a> in February. DeepSeek, a Chinese company, <a href="https://www.benzinga.com/25/01/43232316/deepseek-jitters-shatter-us-tech-stocks-wipe-out-12-trillion-on-wall-street-analyst-eyes-four-chinese-giants-set-to-benefit">released its R1 model</a> in January.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44645681/jpmorgan-raises-recession-risk-to-60-as-largest-us-tax-hike-in-60-years-hits-global-economy">JPMorgan Raises Recession Risk To 60% As &#8216;Largest US Tax Hike&#8217; In 60 Years Hits Global Economy</a></li>
</ul>
Photo: Shutterstock

News

Tech

Sam Altman Backtracks On o3 Cancellation, Plans To Release Model In Anticipation Of GPT-5: 'People Will Be Happy'

Dutch advanced <a target="_blank" href="https://www.benzinga.com/topic/chips" rel="noreferrer noopener">chipmaking equipment supplier</a> ASML Holding NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) stock fell to its 52-week low, hitting $597.69, on Friday after President&nbsp;Donald Trump&nbsp;imposed a 20% tariff on products from the European Union.
ASML makes the most advanced machines used in chip production, known as extreme ultraviolet, or EUV, lithography tools to produce the chips necessary for high-end smartphones and computers, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-04-03/asml-ceo-says-global-tensions-harm-innovation-as-us-tariffs-hit?srnd=phx-technology&amp;sref=TBDibEcD" rel="noreferrer noopener">reports</a>.
The EUV lithography market was worth $10.09 billion in 2023 and could reach&nbsp;$35.70 billion by 2032, implying a CAGR of 15.1% from <a target="_blank" href="https://www.benzinga.com/25/04/44631510/asml-to-boost-japan-workforce-5x-amid-global-race-for-advanced-semiconductor-tech" rel="noreferrer noopener">2024 to 2032</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44630345/samsungs-china-chip-pivot-gains-steam-with-54-export-surge-amid-us-market-struggles" rel="noreferrer noopener">Samsung&#8217;s China Chip Pivot Gains Steam With 54% Export Surge Amid US Market Struggles</a>
The near-term direct impacts could be limited,&nbsp;Thornburg Investment Management told Bloomberg. In 2024, about 16% of ASML&#8217;s net sales came from customer facilities in the U.S..
Still, ASML customers, including&nbsp;Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>),&nbsp;Taiwan Semiconductor Manufacturing Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>), and&nbsp;Samsung Electronics Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>), are ramping up their U.S. operations courtesy of the 25% investment tax credit in the U.S.&nbsp;under the 2022&nbsp;Chips and Science Act.
Dutch Foreign Trade Minister&nbsp;Reinette Klever&nbsp;told Bloomberg that the EU is exploring retaliatory measures.
Reportedly, ASML plans to quintuple Japan maintenance staff as EUV machine demand surges with Rapidus and global chip expansion.
ASML Holding stock has plunged ~36% in the last 12 months. The company disclosed in its&nbsp;annual report that the U.S. semiconductor sanctions on China hurt 2024 demand, with China making up 36% of its sales.
<h2 class="wp-block-heading">ASML Stock Prediction For 2025</h2>
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at ASML Holding, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For ASML Holding, the 200-day moving average sits at $788.16, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, which is above the current price of $608.0. For more on charts and trend lines, <a href="https://pro.benzinga.com/">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
Price Action:&nbsp;ASML stock is up 2.51% at $607.60 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/04/44630304/qualcomm-expands-ai-ambitions-with-acquisition-of-vinais-generative-ai-division" target="_blank" rel="noreferrer noopener">Qualcomm Expands AI Ambitions With Acquisition of VinAI&#8217;s Generative AI Division</a></li>
</ul>
Photo by M.J.J. de Vaan via Shutterstock

Government

Regulations

Media

ASML

INTC

SSNLF

Trump's EU Tariffs Impacts Chip Equipment Giant ASML, Stock Hits 52-Week Low

Politics

General

AMZN

Bytedance Says Any Pact To Be Subject To Approval Under Chinese Law; Says There Are Key Matters To Be Resolved

Progressive shares are trading lower after B of A Securities downgraded the stock from Buy to Neutral and cut its price target from $300 to $287.

Telsey Advisory Group analyst Cristina Fernández shared key points from a meeting with Williams-Sonoma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) CFO Jeff Howie and Chief Accounting Officer &amp; Head <a target="_blank" href="https://www.benzinga.com/quote/wsm/analyst-ratings" rel="noreferrer noopener">of IR Jeremy Brooks this week</a>.
The analyst writes that the company emphasized its strengths, including an $8 billion revenue scale, a strong balance sheet with $1.2 billion in cash and no debt, and supply chain expertise while acknowledging potential tariff headwinds announced by the Trump administration.
Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/25/04/44640787/mark-cuban-warns-of-price-hikessays-buy-consumables-now-before-retailers-blame-tariffs" rel="noreferrer noopener">Mark Cuban Warns Of Price Hikes, Says &#8216;Buy Consumables Now,&#8217; Before Retailers Blame Tariffs</a>
To neutralize the impact of tariffs, the company plans to negotiate with vendors, adjust pricing, enhance supply chain efficiencies, leverage AI for operations, and cut SG&amp;A costs, adds the analyst.
To tackle tariffs, the analyst writes that the company can lower advertising expenses (historically 6.5%- 7.5% of sales) and improve logistics for large home deliveries, which total 2.2 million annually (7,000 per day).
Fernández notes that despite challenges, Williams-Sonoma&#8217;s demand remains stable year-to-date.
The analyst writes Williams-Sonoma is well-positioned to navigate challenges due to its diversified brand portfolio, unique merchandise, supply chain strength, and flexible cost structure.
Overall, the analyst maintained the Outperform rating on the stock <a href="https://www.benzinga.com/quote/WSM/analyst-ratings">with a price forecast of $220.</a>
Price Action: WSM shares are up 3.08% at $143.13 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44634737/retailers-brace-for-higher-costs-as-us-tariff-rates-soar-says-goldman-sachs" target="_blank" rel="noreferrer noopener">Goldman Sachs Warns Tariffs Will Hit Apparel And Home Furnishings Hardest, Highlights Most Exposed Stocks</a></li>
</ul>
Image via Shutterstock.

Analyst Color

Equities

Large Cap

Price Target

Reiteration

Analyst Ratings

Trading Ideas

How Will Williams-Sonoma Offset Tariff Risks?

Blackstone shares are trading lower after B of A Securities cut its price target on the stock from $219 to $207.

KKR shares are trading lower after B of A Securities cut its price target on the stock from $214 to $194.

Johnson &amp; Johnson&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) on Friday announced topline results from Phase&nbsp;3b&nbsp;APEX study of Tremfya (guselkumab) in patients with active psoriatic arthritis (PsA) who are biologic naïve and have had an inadequate <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">response to standard therapies</a>.
The study achieved its primary endpoint (ACR20a) of reducing signs and symptoms and its major secondary endpoint of reducing progression of structural damage as measured by radiographic progression at 24 weeks <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44644676/tremfya-guselkumab-is-the-first-and-only-il-23-inhibitor-to-significantly-reduce-both-the-signs-an" rel="noreferrer noopener">compared to placebo</a>.
In the Phase&nbsp;3b&nbsp;APEX study, Tremfya-treated patients also exhibited significantly less progression of structural damage versus patients receiving a placebo at Week 24 as assessed by the PsA modified van der Heijde-Sharp (vdH-S) score, which includes joint space narrowing and erosion subscores.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44586129/us-judge-rejects-another-johnson-johnson-attempt-to-use-bankruptcy-for-talc-cancer-claims" rel="noreferrer noopener">US Judge Rejects Another Johnson &amp; Johnson Attempt To Use Bankruptcy For Talc Cancer Claims</a>
Data were consistent with the well-established safety profile of Tremfya&nbsp;with no new safety signals identified.
APEX is a Phase&nbsp;3b&nbsp;study with long-term extension data through three years that will further assess the sustained efficacy of Tremfya&nbsp;on inhibition of structural damage in patients with active PsA.
Results from the APEX study are being prepared for presentation at upcoming medical congresses.
<h2 class="wp-block-heading">Johnson &amp; Johnson Stock Prediction For 2025</h2>
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Johnson &amp; Johnson, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Johnson &amp; Johnson, the 200-day moving average sits at $156.5, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, which is above the current price of $155.82. For more on charts and trend lines, <a href="https://pro.benzinga.com/">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
Price Action: JNJ stock is down 3.51% at $154.21 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/buybacks/25/04/44647720/matador-resources-sells-eagle-ford-assets-announces-potential-buybacks" target="_blank" rel="noreferrer noopener">Matador Resources Sells Eagle Ford Assets, Announces Potential Buybacks</a></li>
</ul>
Photo by Tada Images via Shutterstock

Biotech

Health Care

Johnson & Johnson's Tremfya Shows Efficacy In Late-Stage Psoriatic Arthritis Study

Bank of New York Mellon shares are trading lower. Truist Securities cut its price target on the stock from $93 to $90.

Iron ore could be set for further declines, according to Goldman Sachs, which reiterated its short case after concluding field research in China, the largest global consumer of <a href="https://www.benzinga.com/topic/metals">base metals</a>.
The investment bank visited six private steel mills in the Beijing/Tangshan region, evaluating sentiment among mill operators, who forecast a 5% drop in domestic demand in 2025. Although utilization rates are high for now, output is expected to slow as crude steel production cuts take effect in the second half of the year. In parallel, Chinese steel exports are projected to fall by 15% next year, pressured by global protectionism, including recent U.S. tariffs.
Thus, it is straightforward to understand Goldman's pessimistic view of iron ore futures expiring in 2026,&nbsp; which the bank advised as a short as early as last December. Back then, this contract traded at $99.89 per ton and has since come down to around $93. The bank's analysts predict a further drop to $84 per ton in the second half 2025.
Analysts believe President Donald Trump's tariffs will send shockwaves through global trade, negatively impacting Chinese exports to major markets like Vietnam and dampening overall demand. In the short term, the China Mineral Resources Group, the state-owned iron ore buyer, is a crucial stabilizing factor.
Reports suggest that the state entity has an inventory of 10 to 20 million tons at ports and has strategically released supply into the domestic market during tight conditions to help manage price fluctuations.
This situation poses a serious economic threat for Australia, the world's largest iron ore exporter. Mining accounts for 12.2% of the country's economy, nearly half of which is iron ore. A prolonged price drop could seriously hurt the trade balance and reduce government income at a transitional time, as federal elections will be held on May 3.
Last week, the Reserve Bank of Australia kept the cash rate steady at 4.1%, citing uncertainties tied to Trump's tariff plans.
"These developments are expected to have an adverse effect on global activity, especially if households and businesses hold off on spending while waiting for more clarity on the outlook," the bank's board said <a href="https://www.afr.com/policy/economy/rba-leaves-the-cash-rate-on-hold-at-4-1pc-20250331-p5lnyl">per</a> AFR.
However, since then, the tariff announcement has pushed the Australian dollar 5% lower vs. the U.S. dollar, dropping it to the lowest since March 2020 and likely pausing any rate cut plans. If that weakness persists, the next Australian Prime Minister will inherit a hot seat—dealing with a shrinking budget while balancing a tight monetary policy.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44644390/trumps-administration-backs-bidens-legacy-project-to-secure-african-resources">Trump&#8217;s Administration Backs Biden&#8217;s Legacy Project To Secure African Resources</a></li>
</ul>
Photo: Shutterstock

Commodities

Legal

Markets

Iron Ore Set To Slide Further As Trump Tariffs, China Slowdown Collide, Goldman Says

Movers

AREB

American Rebel Holdings Shares Halted On Circuit Breaker To Downside; Up 316%

Goldman Sachs analyst Michael Ng reiterated a <a href="https://www.benzinga.com/quote/WBD/analyst-ratings">Neutral rating</a> on the shares of Warner Bros Discovery Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) with a price forecast of $10.75.
The analyst lowered the first-quarter EBITDA estimate to $2.03 billion ($2.08 billion prior, $2.06 billion Visible Alpha consensus) and revenue to $9.54 billion ($9.80 billion prior, $9.73 billion consensus).
The first-quarter DTC EBITDA forecast was reduced to $259 million (previously $320 million, consensus $287 million), driven by a lower Average Revenue Per User (ARPU) estimate of $7.42 (previously $7.59).
Expected net additions of +4.5 million in the first quarter, fueled by major TV releases like The White Lotus and international market launches, with further growth in the second quarter from Australia, Tele2 Nordic and BluTV Turkey.
ARPU is projected to decline by 5% in the first quarter due to a subscriber mix shift toward lower-ARPU international markets, wholesale growth, and bundling, partially offset by price increases and increased ad loads.
Also Read:<a href="https://www.benzinga.com/25/04/44645277/why-is-ev-maker-mullen-automotive-stock-skyrocketing-today"> Why Is EV Maker Mullen Automotive Stock Surging Today?</a>
Despite short-term EBITDA pressure, WBD is expected to surpass its $1.3 billion 2025 EBITDA target, driven by subscriber growth, new market expansion (Australia, Italy, Germany), content releases and increased AVOD penetration, Ng said.
The analyst raised the EBITDA forecast for linear networks to $1.78 billion (previously $1.64 billion, consensus $1.75 billion), while revenue was adjusted to $4.64 billion (previously $4.59 billion, consensus $4.66 billion).
Advertising revenue is now expected to decline by 14% year-over-year (previously -17%, consensus -15%), supported by strong sports programming (NHL, March Madness) and reduced upfront cancellations, despite softness in general entertainment.
The first-quarter Networks distribution revenue estimate remains at $2.62 billion, with management expecting low single-digit rate increases from new deals, compared to mid-single-digit historically.
WBD has secured five of the six largest pay-TV provider deals. However, some agreements include lower penetration for smaller networks, aligning with the company's strategy to boost Max retention through bundling.
First-quarter Studios EBITDA is now projected at $361 million (previously $484 million, consensus $395 million), with revenue lowered to $2.54 billion (previously $2.79 billion, consensus $2.92 billion) due to underperformance at the box office.
Box office results for Mickey 17 and The Alto Knights fell short, reducing content revenue estimates, though TV licensing and a favorable $200 million Suicide Squad game impairment adjustment provided partial offsets.
Price Action: WBD shares traded lower by 10.75% at $8.18 at last check Friday. 
Read Next: <a href="https://www.benzinga.com/25/04/44634737/retailers-brace-for-higher-costs-as-us-tariff-rates-soar-says-goldman-sachs">Goldman Sachs Warns Tariffs Will Hit Apparel And Home Furnishings Hardest, Highlights Most Exposed Stocks</a>
Photo: Shutterstock

Goldman Sachs Lowers Warner Bros Discovery Q1 Estimates Amid Streaming Challenges

$2.5 million upfront with up to approximately $8.5 million of potential aggregate gross proceeds upon the exercise in full of warrants
Nashville, TN, April 04, 2025 (GLOBE NEWSWIRE) -- American Rebel Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) ("American Rebel" or the "Company"), creator of American Rebel Beer and a designer, manufacturer, and marketer of branded safes, personal security and self-defense products and apparel, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 724,640 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to purchase up to 724,640 shares of common stock and short-term series B warrants to purchase up to 2,173,920 shares of common stock at a purchase price of $3.45 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants in a private placement priced at-the-market under Nasdaq rules. The series A warrants and the short-term series B warrants will have an exercise price of $2.95 per share and will be exercisable immediately upon issuance. The series A warrants will expire five years from the date of issuance and the short-term series B warrants will expire eighteen months from the date issuance. The private placement is expected to close on or about April 7, 2025, subject to the satisfaction of customary closing conditions.
H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.

Offerings

American Rebel Holdings Announces $2.5M Upfront Private Placement Offering, Including 724,640 Shares Of Common Stock, Series A And B Warrants With Potential For $8.5M In Additional Gross Proceeds, Totaling ~$11M; Expected To Close By April 7, 2025

J.P. Morgan analyst Zach Parham shared his view on Magnolia Oil &amp; Gas Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGY#NYSE">MGY</a>) ahead of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44581428/magnolia-oil-gas-schedules-conference-call-for-first-quarter-2025-results" rel="noreferrer noopener">the earnings release on May 1st</a>.
The analyst maintained a Neutral rating on the stock with a price forecast of $24 after updating for <a target="_blank" href="https://www.benzinga.com/quote/MGY/analyst-ratings" rel="noreferrer noopener">first-quarter commodity prices</a>.
Parham writes that Magnolia Oil &amp; Gas remains on track with its 2-rig/1-frac crew program and is committed to keeping capex below 55% of EBITDA.
Despite commodity price volatility, the analyst expects capital expenditure to stay under 50% of EBITDA due to MGY&#8217;s natural gas exposure.
Also, Parham sees positive productivity trends in Giddings and Karnes wells, which could provide a modest production upside to his production estimates.
For FY25, the analyst estimates total volumes of 96.1 MBoe/d (+7% YoY) and oil volumes of 39.4 MBo/d (+3% YoY), aligning with company guidance.
Also, Parham sees FY25 capex of $478 million (in line with consensus) and FCF of $458 million.
Meanwhile, for the first quarter, the analyst expects cash flow per share (CFPS) to be $1.20 and EBITDA to be $251 million (3% above the estimates at $244 million).
The analyst projects first-quarter oil production of 39.0 MBo/d and total production of 94.0 MBoe/d (both on top of consensus).
Moreover, Parham sees a cash return of $77 million for the quarter, including a dividend per share of $0.15 and a share buyback of $48 million.
Price Action: MGY shares are down 10.9% at $20.94 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/downgrades/25/01/43403315/goldman-sachs-forecasts-limited-upside-for-occidental-magnolia-whats-next" target="_blank" rel="noreferrer noopener">Goldman Sachs Forecasts Limited Upside For Occidental &amp; Magnolia: What&#8217;s Next?</a></li>
</ul>
Photo via Shutterstock.

Mid Cap

What To Expect From Magnolia Oil & Gas Q1 Earnings In Volatile Commodity Environment?

NDSN

PCAR

Shares of industrial stocks are trading lower amid macroeconomic concerns due to rising global trade tensions.

SCHW

Charles Schwab shares are trading lower. Truist Securities cut its price target on the stock from $91 to $85.

Wells Fargo shares are trading lower. Truist Securities cut its price target on the stock from $86 to $84.

Citigroup shares are trading lower. Truist Securities cut its price target on the stock from $85 to $84.

Bank of America shares are trading lower. Truist Securities cut its price target on the stock from $53 to $50.

Management

Press Releases

Soleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D.

Soleno Therapeutics to Participate in Upcoming November Investor Conferences

Earnings

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024

Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

Financing

Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC

Soleno Therapeutics to Participate in Upcoming February Investor Conferences

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome

Comments

Soleno Therapeutics

Unusual Options Activity for

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL